239 related articles for article (PubMed ID: 31119459)
21. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.
Gregory RE; Ettinger DS
Drugs; 1998 Feb; 55(2):173-89. PubMed ID: 9506240
[TBL] [Abstract][Full Text] [Related]
22. Prophylaxis versus treatment: is there a better way to manage radiotherapy-induced nausea and vomiting?
Horiot JC
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1018-25. PubMed ID: 15519770
[TBL] [Abstract][Full Text] [Related]
23. Radiotherapy-induced nausea and vomiting (RINV): antiemetic guidelines.
Feyer PCh; Maranzano E; Molassiotis A; Clark-Snow RA; Roila F; Warr D; Olver I
Support Care Cancer; 2005 Feb; 13(2):122-8. PubMed ID: 15592688
[TBL] [Abstract][Full Text] [Related]
24. Optimising antiemetic therapy: what are the problems and how can they be overcome?
Aapro M
Curr Med Res Opin; 2005 Jun; 21(6):885-97. PubMed ID: 15969889
[TBL] [Abstract][Full Text] [Related]
25. Management of radiation-induced nausea and vomiting.
Abdelsayed GG
Exp Hematol; 2007 Apr; 35(4 Suppl 1):34-6. PubMed ID: 17379085
[TBL] [Abstract][Full Text] [Related]
26. New antiemetic drugs.
Roila F; Fatigoni S
Ann Oncol; 2006 Mar; 17 Suppl 2():ii96-100. PubMed ID: 16608997
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of aprepitant in addition to ondansetron in the prevention of nausea and vomiting caused by fractionated radiotherapy to the upper abdomen (AVERT).
Ades S; Halyard M; Wilson K; Ashikaga T; Heimann R; Kumar S; Blackstock W
Support Care Cancer; 2017 May; 25(5):1503-1510. PubMed ID: 28032216
[TBL] [Abstract][Full Text] [Related]
28. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Rubenstein EB
Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
[TBL] [Abstract][Full Text] [Related]
29. Impact and management of chemotherapy/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists/oncology nurses and patients: a cross-sectional multinational survey.
Vidall C; Fernández-Ortega P; Cortinovis D; Jahn P; Amlani B; Scotté F
Support Care Cancer; 2015 Nov; 23(11):3297-305. PubMed ID: 25953380
[TBL] [Abstract][Full Text] [Related]
30. One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients.
Badalamenti G; Incorvaia L; Messina C; Musso E; Casarin A; Ricciardi MR; De Luca I; Bazan V; Russo A
Support Care Cancer; 2019 Sep; 27(9):3593-3597. PubMed ID: 30762142
[TBL] [Abstract][Full Text] [Related]
31. Emerging drugs for chemotherapy-induced emesis.
Navari RM; Province PS
Expert Opin Emerg Drugs; 2006 Mar; 11(1):137-51. PubMed ID: 16503832
[TBL] [Abstract][Full Text] [Related]
32. [Recent improvements in antiemetic therapy].
Roila F; Palladino MA; Ciccarese G; Basurto C
Tumori; 1997; 83(2 Suppl):S3-14. PubMed ID: 9235727
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of granisetron and aprepitant in a patient who failed ondansetron in the prophylaxis of radiation induced nausea and vomiting: a case report.
Rowbottom L; Pasetka M; McDonald R; Hunyh L; Raman S; DeAngelis C; Chow E
Ann Palliat Med; 2015 Jan; 4(1):32-4. PubMed ID: 25813417
[TBL] [Abstract][Full Text] [Related]
34. 5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: can we safely reduce the dose of administered agents?
Aapro M; Blower P
Cancer; 2005 Jul; 104(1):1-18. PubMed ID: 15929119
[TBL] [Abstract][Full Text] [Related]
35. 5-HT3-receptor antagonists in the control of delayed-onset emesis.
Gridelli C
Anticancer Res; 2003; 23(3C):2773-82. PubMed ID: 12926112
[TBL] [Abstract][Full Text] [Related]
36. A pilot study with palonosetron in the prophylaxis of radiation-induced nausea and vomiting.
Ganesh V; Drost L; DeAngelis C; Wan BA; Pasetka M; Chan S; Zhang L; Tsao M; Barnes E; Pulenzas N; Chung H; Zaki P; Yee C; Chow E
Ann Palliat Med; 2018 Apr; 7(2):211-220. PubMed ID: 29764183
[TBL] [Abstract][Full Text] [Related]
37. 2023 Updated MASCC/ESMO Consensus Recommendations: prevention of radiotherapy- and chemoradiotherapy-induced nausea and vomiting.
Ruhlmann CH; Jordan K; Jahn F; Maranzano E; Molassiotis A; Dennis K
Support Care Cancer; 2023 Dec; 32(1):26. PubMed ID: 38097904
[TBL] [Abstract][Full Text] [Related]
38. 5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19).
; Wong RK; Paul N; Ding K; Whitehead M; Brundage M; Fyles A; Wilke D; Nabid A; Fortin A; Wilson D; McKenzie M; Ackerman I; Souhami L; Chabot P; Pater J
J Clin Oncol; 2006 Jul; 24(21):3458-64. PubMed ID: 16849762
[TBL] [Abstract][Full Text] [Related]
39. Nausea and vomiting induced by gastrointestinal radiation therapy: current status and future directions.
Dennis K; Poon M; Chow E
Curr Opin Support Palliat Care; 2015 Jun; 9(2):182-8. PubMed ID: 25872120
[TBL] [Abstract][Full Text] [Related]
40. Chemotherapy-induced nausea and vomiting: which antiemetic for which therapy?
Schwartzberg LS
Oncology (Williston Park); 2007 Jul; 21(8):946-53; discussion 954, 959, 962 passim. PubMed ID: 17715696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
